Ultragenyx Pharmaceutical (RARE) EPS (Weighted Average and Diluted) (2017 - 2026)
Ultragenyx Pharmaceutical (RARE) reported EPS (Weighted Average and Diluted) of -$1.84 for Q1 2026, down 17.2% year-over-year from -$2.22 in Q1 2025, and down 43.75% on a QoQ basis from -$1.28 in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 10 years of EPS (Weighted Average and Diluted) data on file, last reported at -$1.84 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) fell 17.2% year-over-year to -$1.84 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.1 (down 3.92% YoY) and the FY2025 annual result came in at -$5.83, up 7.31% from the prior year.
- EPS (Weighted Average and Diluted) slipped to -$1.84 in Q1 2026 per RARE's latest filing, from -$1.28 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at -$1.17 in Q2 2025 and bottomed at -$3.5 in Q3 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$1.84 (2026), against an average of -$1.9.
- The widest annual swing landed in 2022, when EPS (Weighted Average and Diluted) slumped 224.07%; it then soared 37.22% in 2024.
- Tracing RARE's EPS (Weighted Average and Diluted) over 5 years: stood at -$2.16 in 2022, then surged by 33.33% to -$1.44 in 2023, then increased by 4.17% to -$1.38 in 2024, then increased by 7.25% to -$1.28 in 2025, then slumped by 43.75% to -$1.84 in 2026.
- Per Business Quant, the three latest RARE EPS (Weighted Average and Diluted) figures stand at -$1.84 (Q1 2026), -$1.28 (Q4 2025), and -$1.81 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -1.84 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.84 |
| Dec 31, 2025 | -1.28 |
| Sep 30, 2025 | -1.81 |
| Jun 30, 2025 | -1.17 |
| Mar 31, 2025 | -1.57 |
| Dec 31, 2024 | -1.38 |
| Sep 30, 2024 | -1.40 |
| Jun 30, 2024 | -1.52 |
| Mar 31, 2024 | -2.03 |
| Dec 31, 2023 | -1.44 |
| Sep 30, 2023 | -2.23 |
| Jun 30, 2023 | -2.25 |
| Mar 31, 2023 | -2.33 |
| Dec 31, 2022 | -2.16 |
| Sep 30, 2022 | -3.50 |
| Jun 30, 2022 | -2.26 |
| Mar 31, 2022 | -2.19 |
| Dec 31, 2021 | -1.79 |
| Sep 30, 2021 | -1.08 |
| Jun 30, 2021 | -1.81 |
| Dec 31, 2020 | -0.39 |
| Jun 30, 2020 | 0.41 |
| Mar 31, 2019 | -1.82 |
| Mar 31, 2018 | 0.62 |
| Mar 31, 2017 | -1.63 |